— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022
— SKYTROFA revenue continued to double quarter-to-quarter, reaching €4.4 million in the second quarter
— With anticipated growth in U.S. revenues and approximately €1 billion of cash, cash equivalents, and marketable securities on hand, Ascendis is positioned to fulfill Vision 3x3 and become cash flow positive
https://finance.yahoo.com/news/ascendis-pharma-reports-second-quarter-200100190.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.